Lifecare ASA · OSL:LIFE

Lifecare ASA — Investor Presentation (March 2025)

20 slides from Lifecare ASA's investor presentation, March 2025

  1. Slide 1: Company presentation

    Company presentation Updated March 2025

  2. Slide 2: Disclaimer

    Disclaimer The information in this presentation has been prepared by Lifecare (the “Company”). This presentation does not constitute a recommendation regarding any securities of the Company. By accepting to attend this presentation and/or receive this information, you agree to be bound by the follow

  3. Slide 3: Company presentation agenda

    Company presentation Market & competition Lifecare’s Sencell sensor Clinical studies and progress About Lifecare Ce) LIFECARE

  4. Slide 4: A Global Crisis that Remains Uncontrolled

    A Global Crisis that Remains Uncontrolled Diabetes Diagnosis and Cost Global Diabetes Related Health Expenditures 783m in 2045E USD 463m Hatt a018 in 2019 HERE RTTRETTEA ETT 19) +27% increase Past 2 Years IDF Atlas, 10th ection (2021) EE Ce) LIFECARE 03.03.2025 4

  5. Slide 5: Glucose Monitoring

    Glucose Monitoring Standard treatment Blood Glucose Meter State-of-the art treatment Continuos Glucose Monitor 03.03.2025 5

  6. Slide 6: Sensing principles – Continuous Glucose Monitoring

    Sensing principles – Continuous Glucose Monitoring 1 Glucose oxidase 2 Flourescence 3 Osmotic pressure Dexcom (G6 & G7), Medtronic, Abbott Senseonics (Eversense) Lifecare (Sencell) (FreeStyle Libre 2 & 3) Longevity: 7- 14 days Longevity: 180 days Longevity: 172 days (in-vitro) Annual cost: $ 1.500 –

  7. Slide 7: Clinical stage sensor company developing the world's smallest Continuous Glucose Monitor

    Clinical stage sensor company developing the worlds smallest Continuous Glucose Monitor 03.03.2025 7

  8. Slide 8: Sencell system

    Sencell system ✓ Size of a grain of rice ✓ Injected under the skin ✓ 6 months longevity ✓ No calibration needed 03.03.2025 8

  9. Slide 9: Clinical status

    Study «LFC-SEN-001» – concluded May 2023 Clinical status presented at American Diabetes Association Scientific Sessions June 23 Purpose: Collect human proof-of-concept performance data for algorithm development during meal experiments and for further device optimization Conclusion: Subcutaneous gluc

  10. Slide 10: Clinical accuracy – Consensus error grid

    Clinical accuracy – Consensus error grid (ISO 15197: BG meters) Results in zone A and B: LFC-SEN-001: Retrospective regulatory accepted consensus error-grid analysis 03.03.2025 10

  11. Slide 11: Documented 12 weeks longevity in live tissue

    Documented 12 weeks longevity in live tissue Ongoing longevity study at in cooperation with the Veterinary institute at the Norwegian University of Life Sciences. Implant in dog has shown 12 week functionality with no complications during the period or after explanation. Bacteriological examination

  12. Slide 12: One technology Two markets

    One technology Two markets 03.03.2025 12

  13. Slide 13: The potential of Lifecare Veterinary

    The potential of Lifecare Veterinary USA With diabetes 85 million dogs 1 million 62 million cats 0,25 million Europe With diabetes 90 million dogs 1,1 million 120 million cats 0,5 million Dogs & Cats that develop diabetes every year

  14. Slide 14: Product development agreement with Sanofi

    Product development agreement with Sanofi Sanofi-Avenis Group sponsor the development program for miniaturizing the Sencell Glucose sensor with funding of EUR 290.000 based on completion of defined development phases The Development Agreement is based on a robust evaluation and due diligence process

  15. Slide 15: Progress

    Progress Studies Regulatory compliance Production and market launch Successful in-vitro testing confirming Approval for accuracy study LFC-SEN-001 Production location secured functionality of miniaturized sensors Proof-of-concept in humans In-human study (LFC-SEN-001) ISO 9001 and ISO 13485 certifie

  16. Slide 16: Pilot -> Automated production

    Pilot -> Automated production 03.03.2025 16

  17. Slide 17: Mainz: manufacturing facilities for volume production

    Mainz: manufacturing facilities for volume production 03.03.2025 17

  18. Slide 18: Organization

    Organization Lifecare ASA Lifecare Laboratory Lifecare NanoBioSensors (Bergen, NO) (Mainz, DE) (Reutlingen, DE) Lifecare Chemistry Lifecare Veterinary RemovAid (Bristol UK) (Bergen, NO) (Lysaker, NO)

  19. Slide 19: People

    People Full-time equivalents: 33 PhD: 7 Scientifical workers: 30 PhD-students: 4 03.03.2025 19

  20. Slide 20: Slide 20

Lifecare — Investor Presentation (March 2025) on 6ix